Company / SG&A Expense
Praxis Precision Medicines, Inc. SG&A Expense History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$59.1M
FY2025
5-year range
$42.1M / $59.9M
FY2021-FY2025
Trend
+4.9%
vs FY2024
Sector context
#149 of 213
Health Care
What the data says
At $59M, Praxis Precision Medicines, Inc.'s sg&a expense ranks #65 of 213 in the Health Care sector. Increased from $42M to $59M over the past 2 years.
Based on SEC 10-K filings.
$59M in FY2025 with a 5-year CAGR of +28.3%.
Increased from $42M to $59M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -0.5%
- 5-Year CAGR
- +28.3%
- 10-Year CAGR
- -
Sector benchmark
#65 of 213 in Health CareTop 30% of 213This company $59.1M Sector average $722.3M
▼
-91.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +28.3%, indicating consistent growth.
- In FY2025, sg&a expense increased 4.9% year-over-year.
- Ranks #149 out of 213 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 4.48 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $59.1M | +4.9% |
| FY2024 | $56.3M | +33.9% |
| FY2023 | $42.1M | -29.8% |
| FY2022 | $59.9M | +27.3% |
| FY2021 | $47.1M | +177.0% |
| FY2020 | $17.0M | +172.7% |
| FY2019 | $6.2M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026